<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03927326</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00007182</org_study_id>
    <nct_id>NCT03927326</nct_id>
  </id_info>
  <brief_title>Postoperative Analgesia in Laparoscopic Abdominal Surgery After Exparel Via TAP or Local Infiltration</brief_title>
  <official_title>On Postoperative Analgesic Requirements in Laparoscopic Colorectal Surgery Patients After Exparel Administration Via Transversus Abdominis Plane Block Versus Surgical Infiltration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates differences in how administering liposomal bupivacaine via two different
      methods affects postoperative pain control in laparoscopic abdominal surgery patients. Half
      the participants will receive liposomal bupivacaine via a transverses abdominis plane block
      while the other half will receive liposomal bupivacaine via local infiltration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Liposomal bupivacaine is a newer formulation of a local anesthetic that is commonly used for
      local infiltration, peripheral nerve blocks, and neuraxial anesthesia. This new formulation
      allows the effects of bupivacaine to last up to 72 hours as it is slowly released from a
      liposome. It is FDA approved for local infiltration and has recently been approved for
      interscalene blocks.

      A transversus abdominis plane block is a fascial plane block that is performed routinely for
      postoperative pain relief for some abdominal incisions. It is performed by placing local
      anesthetic between the internal oblique and transverses abdominis muscle planes where it will
      provide analgesia to several dermatomes of the abdomen in hopes of improving postoperative
      pain relief and reducing postoperative opioid requirement.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2019</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Unblinded randomized trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>24 hour post operative opioid consumption</measure>
    <time_frame>24 hours postoperative</time_frame>
    <description>Listed in morphine daily equivalents.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>12 hour post operative opioid consumption</measure>
    <time_frame>12 hours postoperative</time_frame>
    <description>Listed in morphine daily equivalents</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>48 hour post operative opioid consumption</measure>
    <time_frame>48 hours postoperative</time_frame>
    <description>Listed in morphine daily equivalents</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain intensity at 12 hours post operative</measure>
    <time_frame>12 hours</time_frame>
    <description>Self reported pain intensity by visual analog scale scored 0-10 (0 = no pain; 10 = worst pain imaginable)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain intensity at 24 hours post operative</measure>
    <time_frame>24 hours</time_frame>
    <description>Self reported pain intensity by visual analog scale scored 0-10 (0 = no pain; 10 = worst pain imaginable)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>Until end of hospital stay, typically 3 days</time_frame>
    <description>How long the patient requires their inpatient stay measured in days.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Pain, Postoperative</condition>
  <condition>Anesthesia, Local</condition>
  <condition>Anesthesia; Functional</condition>
  <condition>Anesthesia</condition>
  <condition>Opioid Use</condition>
  <arm_group>
    <arm_group_label>Local infiltration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liposomal bupivacaine (266mg) will be directly infiltrated by the surgeon into the surgical laparoscopic wound sites.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Transversus abdominis plane block</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liposomal bupivacaine (266mg) will be used in a ultrasound guided transversus abdominis plane block.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exparel 266 MG Per 20 ML Injection</intervention_name>
    <description>Liposomal bupivacaine</description>
    <arm_group_label>Local infiltration</arm_group_label>
    <arm_group_label>Transversus abdominis plane block</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled for elective laparoscopic colorectal surgery at UWMC requiring
             inpatient stay

        Exclusion Criteria:

          -  Patients on chronic pain mediations equaling or exceeding &gt; 25 morphine daily
             equivalents

          -  Patients allergic to bupivacaine

          -  Patients with ASA status IV, V, or VI

          -  Patients unable to consent

          -  Patients that are pregnant

          -  Patients that are incarcerated

          -  Patients receiving procedures in addition to laparoscopic colorectal procedure

          -  Patients on systemic anticoagulation precluding them from regional blocks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vanessa Loland, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alan Chang, MD</last_name>
    <phone>714-878-0850</phone>
    <email>achang5@uw.edu</email>
  </overall_contact>
  <reference>
    <citation>Bergese SD, Ramamoorthy S, Patou G, Bramlett K, Gorfine SR, Candiotti KA. Efficacy profile of liposome bupivacaine, a novel formulation of bupivacaine for postsurgical analgesia. J Pain Res. 2012;5:107-16. doi: 10.2147/JPR.S30861. Epub 2012 May 1.</citation>
    <PMID>22570563</PMID>
  </reference>
  <reference>
    <citation>Gorfine SR, Onel E, Patou G, Krivokapic ZV. Bupivacaine extended-release liposome injection for prolonged postsurgical analgesia in patients undergoing hemorrhoidectomy: a multicenter, randomized, double-blind, placebo-controlled trial. Dis Colon Rectum. 2011 Dec;54(12):1552-9. doi: 10.1097/DCR.0b013e318232d4c1.</citation>
    <PMID>22067185</PMID>
  </reference>
  <reference>
    <citation>Mulligan RP, Morash JG, DeOrio JK, Parekh SG. Liposomal Bupivacaine Versus Continuous Popliteal Sciatic Nerve Block in Total Ankle Arthroplasty. Foot Ankle Int. 2017 Nov;38(11):1222-1228. doi: 10.1177/1071100717722366. Epub 2017 Aug 8.</citation>
    <PMID>28786304</PMID>
  </reference>
  <reference>
    <citation>Sternlicht A, Shapiro M, Robelen G, Vellayappan U, Tuerk IA. Infiltration of liposome bupivacaine into the transversus abdominis plane for postsurgical analgesia in robotic laparoscopic prostatectomy: a pilot study. Local Reg Anesth. 2014 Dec 12;7:69-74. doi: 10.2147/LRA.S64515. eCollection 2014. Review.</citation>
    <PMID>25540595</PMID>
  </reference>
  <reference>
    <citation>Hadzic A, Abikhaled JA, Harmon WJ. Impact of volume expansion on the efficacy and pharmacokinetics of liposome bupivacaine. Local Reg Anesth. 2015 Dec 7;8:105-11. doi: 10.2147/LRA.S88685. eCollection 2015. Review.</citation>
    <PMID>26673040</PMID>
  </reference>
  <reference>
    <citation>Candiotti KA, Sands LR, Lee E, Bergese SD, Harzman AE, Marcet J, Kumar AS, Haas E. Liposome Bupivacaine for Postsurgical Analgesia in Adult Patients Undergoing Laparoscopic Colectomy: Results from Prospective Phase IV Sequential Cohort Studies Assessing Health Economic Outcomes. Curr Ther Res Clin Exp. 2013 Dec 27;76:1-6. doi: 10.1016/j.curtheres.2013.12.001. eCollection 2014 Dec.</citation>
    <PMID>25031661</PMID>
  </reference>
  <reference>
    <citation>Gastevski D. Infiltration of liposome bupivacaine into the transversus abdominis plane for postsurgical pain management in a 39-year-old female undergoing laparoscopic cholecystectomy. Pain Med. 2014 Aug;15(8):1312-5. doi: 10.1111/pme.12356. Epub 2014 Jan 21.</citation>
    <PMID>24612211</PMID>
  </reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 18, 2019</study_first_submitted>
  <study_first_submitted_qc>April 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2019</study_first_posted>
  <last_update_submitted>April 23, 2019</last_update_submitted>
  <last_update_submitted_qc>April 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Alan Chang</investigator_full_name>
    <investigator_title>Resident, School of Medicine: Anesthesiology and Pain Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>We are not planning on making IPD available to other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

